-The Hindu With the Rajya Sabha Standing Committee on Health expressing concern over the high cost of cancer treatment, the Government invoking Section 100 of the Patents Act is a way forward The subject of the spiralling costs of Cancer Medicines and their implications that have frequently been highlighted the world over were dwelled on in a recent report (“Cancer Care Plan and Management”) by the Rajya Sabha’s Standing Committee on Health....

-GaonConnection.com At least ten districts of Bihar have reported high levels of uranium in their groundwater, the primary source of drinking water in rural areas, which far exceeds the tolerable limit prescribed by the World Health Organization. Millions in Bihar are already facing a high disease burden due to elevated levels of arsenic, fluoride and iron in their water. Presence of uranium has multiplied their worries manifold. The state government is...

The rise in COVID-19 daily new cases and daily new deaths compelled many state governments to impose local level lockdowns during April-May 2021. As of 20th April, 2021, partial lockdowns were noticed in 10 states across the country and complete lockdown was imposed in Delhi. As of 8th May, 2021, nearly the entire country was under complete lockdown as a result of either partial lockdowns and night curfews or complete...

-Financial Express If patents continue to determine global access to vaccines and drugs, then fighting Covid-19 will remain a distant dream for most countries Vaccines are badly required by the world, as are drugs like Remdesivir and Tocilizumab, and medical equipment like ventilators and oxygen concentrators. A large number of countries, particularly low- and middle-income ones, are struggling to access vaccines, drugs and equipment. There cannot be a more important occasion than the...

-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and rare diseases are out of reach of many due to their unaffordable prices,...